Delivery Order SPE2DB20D1100-SPE2DB25FD9L2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Creon DR 36,000 unit capsules in quantities of 100 units. This non-set-aside, firm fixed-price delivery order has a ceiling value of $6,733.40 and is scheduled for ultimate completion by August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $5,467.17. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is performable at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 4, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Creon DR 36,000 unit capsules in 100-count packages, with a contract value of $3,339.59 and completion date of August 22, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award supporting federal pharmaceutical procurement needs. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $14,406.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for 36,000 unit capsules of Creon (pancrelipase) in 100-count packages, with completion scheduled for September 10, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award is non-set-aside and was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $31,396.02. This firm fixed price delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for 24,000 units of Creon DR 100s capsules, a pancreatic enzyme supplement medication. This competitively awarded, non-set-aside contract carries a ceiling value of $3,042.77 and is classified as a firm fixed price delivery order with an ultimate completion date of August 27, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 24,000 unit capsules of Creon DR 100s, with a ceiling value of $8,755.73 and a firm fixed price structure. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is scheduled for completion by August...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication. This firm fixed-price delivery order, valued at $11,775.31, represents a competitively awarded contract with an ultimate completion date of August 29, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied to...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD9L2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company holds a significant competitive position with the Defense Logistics Agency, with its contract awards covering an extensive portfolio of medications and medical supplies across multiple therapeutic domains. This delivery order for Creon DR, a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency, represents a routine pharmaceutical supply transaction supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/8/25 |